Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

41

9:35 Spotlight on Post-Hospitalization Rehabilitation P. Camp, PT, PhD, Vancouver, Canada 9:55 Patient Speaker Speaker To Be Announced 10:00 Strategies for Implementation of the New Guidelines N.S. Cox, PT, MSci, PhD, Melbourne, Australia 10:15 Panel and Audience Discussion

10:17 Leveraging Multilevel Profiling of Longitudinal Cohort Participants to Illuminate COPD Endotypes M.R. Faner, PhD, BSc, Barcelona, Spain This session and the International Conference are supported by an independent medical educational grant from AstraZeneca LP. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BASIC • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

CME Credits Available: 1.5 MOC Points Available: 1.5

A8

BRONCHOPULMONARY DYSPLASIA ACROSS THE LIFESPAN

A7 THE NEW ATS CLINICAL PRACTICE GUIDELINES FOR PULMONARY REHABILITATION Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research 9:00 AM - 10:30 AM Walter E. Washington Convention Center Room 143 A-C (Street Level) Target Audience Clinicians and researchers working with patients with chronic respiratory disease, in particular those involved in PR, as well as patients, care givers and patient advocacy groups with an interest in PR. Objectives At the conclusion of this session, the participant will be able to: • describe the current evidence underpinning the new PR clinical practice guidelines • apply the new clinical practice guidelines into current practice • better understanding of the evidence and implementation of clinical practice guidelines for PR will improve the quality of life/health status of this patient group Attendees will develop an understanding of the new pulmonary rehabilitation (PR) clinical practice guidelines, recommendations across the spectrum of chronic lung disease and the evidence that underpin this guidance. The session will also give practical tips on how to implement this guidance. Chairing: L. Houchen-Wolloff, PhD, Leicester, United Kingdom S.P. Bhatt, MD, MSPH, Birmingham, AL 9:00 Rationale for New ATS Clinical Practice Guidelines in Pulmonary Rehabilitation C.L. Rochester, MD, New Haven, CT 9:10 Overview of New Guidelines A.E. Holland, PT, PhD, Melbourne, Australia

Assembly on Pediatrics 9:00 AM - 10:30 AM

Marriott Marquis Washington Marquis Ballroom Salon 6 (Level M2)

Target Audience Neonatologists, pediatric pulmonologists, pediatric radiologists, respiratory therapists, adult pulmonary critical care specialists, and basic science researchers interested in pulmonary development and molecular mechanisms of lung injury Objectives At the conclusion of this session, the participant will be able to: • to describe new findings about pre- and postnatal molecular mechanisms of lung injury that may plausibly serve as therapeutic targets that mitigate severe respiratory disease trajectories in preterm at risk for BPD • to integrate new guidelines into current practice related to the multidisciplinary care of children with established BPD with focus on: multidisciplinary BPD care programs, pulmonary vascular disease, and the application of advanced imaging • to improve the quality of life/health status of patients with BPD by understanding how longitudinal pulmonary function trajectories in childhood, adolescence, and adulthood are modified by BPD Bronchopulmonary dysplasia (BPD), the chronic lung disease of infancy, is the most common morbidity of preterm birth. Despite improvements in the respiratory care of infants born preterm, the incidence of BPD is increasing, owing to the improved survival of infants born extremely preterm. As increasing numbers of preterm infants survive to adulthood, BPD is increasingly recognized as an important contributor to morbidity and mortality throughout life even into adulthood. This session will situate current information regarding the molecular mechanisms of BPD pathogenesis within the context of longitudinal state-of-the-art, evidence-based respiratory care practices and outcomes research of individuals with established BPD.

ATS 2023 • Washington, DC